Basic Information
| LncRNA/CircRNA Name | NKILA |
| Synonyms | AK056098 |
| Region | GRCh38_20:57710183-57712780 |
| Ensemble | ENSG00000278709 |
| Refseq | NR_131157 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc. |
| Sample | cell line (QSG-7701, SMMC-7721, Hep3B, HCCLM3, HepG2), HCC tissues |
| Expression Pattern | down-regulated |
| Function Description | NKILA is down-regulated in HCC and reduced expression of NKILA indicts poor survival of HCC patients. Overexpression of NKILA enhances the roles of baicalein on HCC cell proliferation inhibition, apoptosis induction, and migration inhibition in vitro and tumor growth suppression in vivo. Conversely, knockdown of NKILA suppresses the effects of baicalein. Mechanistically, we found that NKILA inhibits IkBa phosphorylation, NF-kB nuclear translocation, and NF-kB activity. NKILA also enhances the inhibitory effects of baicalein on NF-kB signaling. Furthermore, the effects of NKILA on baicalein-induced NF-kB activity inhibition, cell growth inhibition, apoptosis induction, and migration inhibition are reversed by NF-kB nuclear translocation inhibitor JSH-23. |
| Pubmed ID | 29481769 |
| Year | 2018 |
| Title | Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-kB signaling. |
External Links
| Links for NKILA | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |